Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Study of ssCART-19 Cells in Patients With CD19 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia

NCT04825496 is registered in ClinicalTrials.gov with Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd as lead sponsor.

NCT NCT04825496
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04825496 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Study of ssCART-19 Cells in Patients With CD19 Positive Relapsed or Refractory Acute Lymphoblastic Leukemia
Lead sponsor
Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd
Phase
Phase 1
Overall status
Unknown status
Start date
April 9, 2021
Completion date
December 31, 2024
Enrollment
18 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed or refractory acute lymphoblastic leukemia